Chemomab Therapeutics (CMMB) Accumulated Expenses (2017 - 2025)
Chemomab Therapeutics (CMMB) posted Accumulated Expenses of $337000.0 for Q4 2025, down 27.37% on a QoQ basis from $464000.0 in Q3 2025, and down 63.92% year-over-year from $934000.0 in Q4 2024.
Chemomab Therapeutics (CMMB) Accumulated Expenses (2017 - 2025) Analysis & Trends
Chemomab Therapeutics' Accumulated Expenses history runs 9 years deep, the most recent figure standing at $337000.0 for Q4 2025.
- Quarterly Accumulated Expenses fell 63.92% year-over-year to $337000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $337000.0 (down 63.92% YoY) and the FY2025 annual result came in at $337000.0, down 63.92% from the prior year.
- Accumulated Expenses was $337000.0 for Q4 2025 at Chemomab Therapeutics, down from $464000.0 in the prior quarter.
- Across five years, Accumulated Expenses topped out at $3.4 million in Q4 2023 and bottomed at $337000.0 in Q4 2025.
- A 5-year average of $1.7 million and a median of $1.4 million in 2022 frame the typical range for Accumulated Expenses.
- Annual changes were most pronounced in 2022 — Accumulated Expenses surged 238.58% — and 2025, when it tumbled 85.15%.
- Chemomab Therapeutics' Accumulated Expenses stood at $653000.0 in 2021, then surged by 138.9% to $1.6 million in 2022, then jumped by 119.42% to $3.4 million in 2023, then sank by 72.71% to $934000.0 in 2024, then sank by 63.92% to $337000.0 in 2025.
- Business Quant data shows CMMB's Accumulated Expenses at $337000.0 in Q4 2025, $464000.0 in Q3 2025, and $666000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Chemomab Therapeutics | 124.14 Mn | 113.77 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 337,000.00 |
| Sep 30, 2025 | 464,000.00 |
| Jun 30, 2025 | 666,000.00 |
| Mar 31, 2025 | 1.37 Mn |
| Dec 31, 2024 | 934,000.00 |
| Sep 30, 2024 | 3.12 Mn |
| Jun 30, 2024 | 2.55 Mn |
| Mar 31, 2024 | 3.40 Mn |
| Dec 31, 2023 | 3.42 Mn |
| Sep 30, 2023 | 3.01 Mn |
| Jun 30, 2023 | 2.50 Mn |
| Mar 31, 2023 | 3.16 Mn |
| Dec 31, 2022 | 1.56 Mn |
| Sep 30, 2022 | 1.53 Mn |
| Jun 30, 2022 | 1.71 Mn |
| Mar 31, 2022 | 1.25 Mn |
| Dec 31, 2021 | 653,000.00 |
| Sep 30, 2021 | 451,000.00 |
| Jun 30, 2021 | 977,000.00 |
| Mar 31, 2021 | 523,000.00 |